Clinical efficacy of azithromycin for treatment of Mycoplasma pneumoniae pneumonia with gene mutations at site A2063G of 23S rRNA in children
10.13406/j.cnki.cyxb.003783
- VernacularTitle:阿奇霉素治疗23S rRNA的A2063G基因位点突变肺炎支原体肺炎患儿的临床观察
- Author:
Wen LI
1
;
Tongyong LUO
;
Fei WANG
;
Bo ZHANG
;
Yongxian JIANG
;
Siqi HU
Author Information
1. 四川省妇幼保健院/四川省妇女儿童医院/成都医学院附属妇女儿童医院临床药学科,成都 610041
- Keywords:
azithromycin;
macrolide resistance;
mycoplasma pneumonia;
23S rRNA resistance gene
- From:
Journal of Chongqing Medical University
2025;50(11):1569-1572
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the clinical efficacy of azithromycin for the treatment of Mycoplasma pneumoniae pneumonia(MPP)with gene mutations at site A2063G of 23S rRNA in children.Methods:Data were retrospectively collected for 242 children diagnosed with MPP at Sichuan Provincial Maternity and Child Health Care Hospital from January to December 2023,in whom MPP was detected using targeted next-generation sequencing(tNGS).According to the presence or absence of mutations,the children were classified into mutation group(88 cases)and non-mutation group(154 cases).Results:Gene mutations at site A2063G of 23S rRNA were detected in 88 patients.The chest X-rays of both groups showed more lesions in the right lung than in the left lung.Both groups were treated with azithromycin and compared for differences in age,sex,duration of fever,C-reactive protein level,time to improvement of chest X-rays,days of medication,and response rate,with no significant differences found in the above indicators(P>0.05).However,the duration of respiratory symptoms was significantly longer in the mutation group than in the non-mutation group[(11.51±3.31)d vs.(10.06±3.63)d,P<0.05].Conclusion:Azithromycin is effective in treating MPP with gene mutations at site A2063G of 23S rRNA.
